Thermo Fisher Scientific | TMO - Current Liabilities


Thermo Fisher Scientific reported $15.07B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Agilent USD 2.27B 35M Mar/2026
Becton, Dickinson and Co. USD 8.51B 254M Mar/2026
Bio Techne USD 153.28M 12.85M Mar/2026
Bio-Rad Laboratories USD 961.3M 44.3M Jun/2026
Boston Scientific USD 6.43B 1.86B Jun/2026
Bruker USD 1.2B 150.4M Jun/2026
Charles River Laboratories USD 1.09B 26.61M Mar/2026
Danaher USD 8.1B 645M Jun/2026
Dentsply International USD 1.21B 136M Mar/2026
Edwards Lifesciences USD 1.51B 98.9M Jun/2026
General Electric Aerospace USD 40.43B 403M Jun/2026
Henry Schein USD 3.49B 191M Jun/2026
Illumina USD 1.58B 12M Jun/2026
Intuitive Surgical USD 2.58B 65.1M Jun/2026
IQVIA Holdings USD 8.82B 486M Jun/2026
Laboratory Of America USD 2.12B 516.4M Jun/2026
Medtronic USD 9.5B 440M Dec/2025
Mettler Toledo International USD 1.2B 92.14M Jun/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Olympus JPY 436.87B 36.14B Mar/2026
OraSure Technologies USD 44.08M 4.29M Mar/2026
Quest Diagnostics USD 1.79B 389M Jun/2026
Repligen USD 132.66M 6.45M Jun/2026
Revvity USD 1.28B 37.71M Jun/2026
Stryker USD 6.68B 369M Jun/2026
Thermo Fisher Scientific USD 15.07B 448M Jun/2026
Veracyte USD 62.74M 6.62M Jun/2026
Waters USD 2.27B 1.03B Mar/2026
Zimmer Biomet Holdings USD 2.86B 280.6M Mar/2026